1. Volume 15, Issue 1, Pages 33-43 (January 2013)
Cell therapy with bone marrow stromal cells after intracerebral hemorrhage: impact of platelet-rich plasma scaffolds 
Jesus Vaquero, Laura Otero, Celia Bonilla, Concepcion Aguayo, Miguel A. Rico, Alicia Rodriguez, Mercedes Zurita 
Cytotherapy 
Volume 15, Issue 1, Pages (January 2013)
DOI: /j.jcyt
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions

2. Figure 1
Characterization of BMSCs by flow cytometry. Rat BMSCs were labeled with CD29, CD90, CD11b, CD45 or CD31 antibodies and analyzed by flow cytometry. The rat BMSC population was identified based on forward scatter (FSC) and side scatter (SSC) properties. Of the BMSC population, ≥95% must express CD29 and CD90. Additionally, these cells must lack expression (≤5% positive) of CD11b, CD45 or CD31.
Cytotherapy  , 33-43DOI: ( /j.jcyt )
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions

3. Figure 2
(A) Rotarod test. Animals treated with BMSCs embedded in the PRP-derived scaffold started to show significant differences compared with animals treated with BMSCs in saline in the 6th month (P< 0.05). We did not see improvement throughout the study in either the saline-treated group or the PRP-derived scaffold group. (B) Locomotor activity test. Animals treated with BMSCs embedded in the PRP-derived scaffold started to show a significantly higher score (P< 0.05) than animals treated with BMSCs in saline from the 4th month. Animals treated with saline and the PRP-derived scaffold without BMSCs did not show improvement throughout the follow-up period.
Cytotherapy  , 33-43DOI: ( /j.jcyt )
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions

4. Figure 3
Macroscopic views of the brains at the end of follow-up. Brain and coronal section in an animal that received intracerebral BMSCs in saline (left). Brain and coronal section in an animal that received intracerebral administration of saline only (middle). Brain and coronal section in an animal that received BMSCs embedded in a PRP-derived scaffold (right).
Cytotherapy  , 33-43DOI: ( /j.jcyt )
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions

5. Figure 4
Inmunohistochemical expression of Nestin antibody in the different groups. (A) BMSCs in PRP-derived scaffold, SVZ. (B) BMSCs in saline, SVZ. (C) BMSCs in PRP-derived scaffold, LZ. (D) BMSCs in saline, LZ. (E) PRP-derived scaffold only, SVZ. (F) PRP-derived scaffold only, LZ. (G) Saline only, SVZ. (H) Saline only, LZ.
Cytotherapy  , 33-43DOI: ( /j.jcyt )
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions

6. Figure 5
Inmunohistochemical expression of Doublecortin antibody in the different groups. (A) BMSCs in PRP-derived scaffold, SVZ. (B) BMSCs in saline, SVZ. (C) BMSCs in PRP-derived scaffold, LZ. (D) BMSCs in saline, LZ. (E) PRP-derived scaffold only, SVZ. (F) PRP-derived scaffold only, LZ. (G) Saline only, SVZ. (H) Saline only, LZ.
Cytotherapy  , 33-43DOI: ( /j.jcyt )
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions

7. Figure 6
Representation of the number of Ki-67-positive cells in LZ and SVZ of the different groups of the series.
Cytotherapy  , 33-43DOI: ( /j.jcyt )
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions

8. Figure 7
Immunohistochemical findings at the level of the LZ in rats treated with BMSCs embedded in the PRP-derived scaffold. (A) Double immunostain for SrY gene (red) and NeuN (green) shows that some transplanted BMSCs can transdifferentiate to neurons and survive long-term after the transplantation procedure. (B) Double immunostain for SrY gene (red) and GFAP (green) shows that some transplanted BMSCs can transdifferentiate to astroglial cells and survive long-term after the transplantation procedure.
Cytotherapy  , 33-43DOI: ( /j.jcyt )
Copyright © 2013 International Society for Cellular Therapy Terms and Conditions